Develops mRNA-modified CAR-T cell therapies for autoimmune diseases, including myasthenia gravis and myositis, for patients receiving treatment from physicians.
10-K for FY2025, filed Mar 9, 2026We are a late clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases. We leverage our…View ↗
Descartes-08, our lead cell therapy product candidate, is an autologous CAR-T product targeting B-cell maturation antigen, or BCMA, in…View ↗
Based on efficacy and safety data observed in our clinical trials thus far, we believe our cell therapies have the potential to deliver…View ↗
$2.8M
10-K for FY2025, filed Mar 9, 2026
$2.8M ↗
The company develops therapies for autoimmune diseases, with treatment administered to patients by their treating physicians. Its revenue has come primarily from collaborators and licensees funding research and development through upfront and milestone payments, royalties, and expense reimbursements.
10-K for FY2025, filed Mar 9, 2026Based on efficacy and safety data observed in our clinical trials thus far, we believe our cell therapies have the potential to deliver…View ↗
To date, we have not generated any revenue from product sales. Our revenue consists primarily of collaboration and license revenue, which…View ↗
The terms of the Company’s arrangements typically include one or more of the following: (i) upfront fees; (ii) milestone payments related…View ↗
No. It lost $130.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$11.5MView ↗
8-K, filed Jun 9, 2026
On June 9, 2026, Cartesian Therapeutics, Inc. (the “Company”) issued a press release announcing its entry into a strategic licensing…View ↗
Shrinking. Revenue fell 97% in 4 years, from $85.1M in FY2021 to $2.8M in FY2025, about 57% a year.
From immune-tolerance platforms to mRNA cell therapy
The older report described ImmTOR-based therapies for biologic and gene therapy applications and autoimmune disease. The latest report centers on mRNA-modified CAR-T cell therapy candidates for autoimmune diseases.
10-K for FY2022, filed Mar 2, 2023 10-K for FY2025, filed Mar 9, 2026
Competes with Amgen, Argenx, UCB, Johnson & Johnson, AstraZeneca, Kyverna Therapeutics, Cabaletta Bio, Novartis, Gilead Sciences, and Bristol-Myers Squibb
10-K for FY2025, filed Mar 9, 2026Descartes-08 may compete with products of other companies in the MG market, including Amgen, Argenx SE, UCB S.A., Johnson & Johnson through…View ↗
Loading...